Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Mesothelioma

Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_3648-4

Synonyms

Definition

Mesotheliomas are tumors derived from mesothelial cells that form the membranes surrounding the lungs, pericardium, and peritoneum. Mesotheliomas are highly aggressive malignancies, with a median survival of 9 months from diagnosis. The incidence of mesothelioma is higher in men than in women (8:1), and these tumors usually occur during the seventh and eighth decades of life. Mesothelioma is usually associated with occupational asbestos exposure or to exposure to erionite, a mineral fiber that shares some physical characteristics with crocidolite asbestos. The latter is an amphibole form of asbestos. Iron predominates over magnesium in its composition. Following inhalation, it is strongly carcinogenic.

Genetic predisposition to mineral fiber carcinogenesis may contribute to multiple cases of mesothelioma within the same family. There are 3,000 cases of mesothelioma per year in the USA and more than 1,000 in England and Italy. The incidence of...

Keywords

Focal Adhesion Kinase Mesothelial Cell Synovial Sarcoma Malignant Mesothelioma Uveal Melanoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access

References

  1. Altomare DA, Vaslet CA, Skele KL et al (2005) A mouse model recapitulating molecular features of human mesothelioma. Cancer Res 65:8090–8095PubMedCrossRefGoogle Scholar
  2. Carbone M, Emri S, Dogan UA et al (2007) A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. Nat Rev Cancer 7:147–154PubMedCrossRefGoogle Scholar
  3. Carbone M, Yang H, Pass HI, et al. (2013) BAP1 and cancer. Nat Rev Cancer 13:153–159.PubMedPubMedCentralCrossRefGoogle Scholar
  4. Pass HI, Lott D, Leonardo F et al (2005) Asbestos exposure, pleural mesothelioma and osteopontin levels. N Engl J Med 353:1564–1573PubMedCrossRefGoogle Scholar
  5. Testa JR, Cheung M, Pei J, et al. (2011) Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 43:1022–1025.PubMedPubMedCentralCrossRefGoogle Scholar
  6. Xu J, Kadariya Y, Cheung M, Pei J, et al. (2014) Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma. Cancer Res 74:4388–4397.PubMedPubMedCentralCrossRefGoogle Scholar
  7. Yang H, Bocchetta M, Krocznyska B et al (2006) TNF-alpha inhibits asbestos-induced cytotoxicity via a NFkB dependent pathway, a possible mechanism for asbestos induced oncogenesis. Proc Natl Acad Sci U S A 103:10397–10402PubMedPubMedCentralCrossRefGoogle Scholar

See Also (part 1)

  1. (2012) Allelic loss. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 137. doi:10.1007/978-3-642-16483-5_186Google Scholar
  2. (2012) Biopsy. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 415. doi:10.1007/978-3-642-16483-5_644Google Scholar
  3. (2012) Calretinin. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 602. doi:10.1007/978-3-642-16483-5_6743Google Scholar
  4. (2012) Carcinogen. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 644. doi:10.1007/978-3-642-16483-5_839Google Scholar
  5. (2012) Cell cycle. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 737. doi:10.1007/978-3-642-16483-5_994Google Scholar
  6. (2012) CD15. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 693. doi:10.1007/978-3-642-16483-5_921Google Scholar
  7. (2012) Cdc42. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 704. doi:10.1007/978-3-642-16483-5_955Google Scholar
  8. (2012) Chromosomal aberrations. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 838. doi:10.1007/978-3-642-16483-5_1138Google Scholar
  9. (2012) Crocidolite. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 998. doi:10.1007/978-3-642-16483-5_1378Google Scholar
  10. (2012) Cytokeratins. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 1051. doi:10.1007/978-3-642-16483-5_1472Google Scholar
  11. (2012) Deletion. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 1080. doi:10.1007/978-3-642-16483-5_1553Google Scholar
  12. (2012) Epithelial cell. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, pp 1291–1292. doi:10.1007/978-3-642-16483-5_1958Google Scholar
  13. (2012) Erionite. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 1307. doi:10.1007/978-3-642-16483-5_1986Google Scholar
  14. (2012) Exon. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 1360. doi:10.1007/978-3-642-16483-5_2059Google Scholar
  15. (2012) FISH. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, pp 1415–1416. doi:10.1007/978-3-642-16483-5_2197Google Scholar
  16. (2012) FOS. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 1446. doi:10.1007/978-3-642-16483-5_2252Google Scholar
  17. (2012) Genetic susceptibility. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 1528. doi:10.1007/978-3-642-16483-5_2384Google Scholar
  18. (2012) Heterotopia. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 1689. doi:10.1007/978-3-642-16483-5_6744Google Scholar
  19. (2012) Homozygous deletion. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 1729. doi:10.1007/978-3-642-16483-5_2807Google Scholar
  20. (2012) JUN. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 1929. doi:10.1007/978-3-642-16483-5_3186Google Scholar
  21. (2012) Knock-out mouse. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 1957. doi:10.1007/978-3-642-16483-5_3239Google Scholar
  22. (2012) Laparoscopy. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 1979. doi:10.1007/978-3-642-16483-5_3276Google Scholar
  23. (2012) Loss of heterozygosity. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, pp 2075–2076. doi:10.1007/978-3-642-16483-5_3415Google Scholar

See Also (part 2)

  1. (2012) Mesothelial cells. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 2241. doi:10.1007/978-3-642-16483-5_3646Google Scholar
  2. (2012) Monosomy. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 2372. doi:10.1007/978-3-642-16483-5_3831Google Scholar
  3. (2012) Mutagenic. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 2412. doi:10.1007/978-3-642-16483-5_3909Google Scholar
  4. (2012) Onconase. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 2632. doi:10.1007/978-3-642-16483-5_4232Google Scholar
  5. (2012) P53. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 2747. doi:10.1007/978-3-642-16483-5_4331Google Scholar
  6. (2012) Point mutation. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 2934. doi:10.1007/978-3-642-16483-5_4653Google Scholar
  7. (2012) PRb. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 2967. doi:10.1007/978-3-642-16483-5_4708Google Scholar
  8. (2012) Promoter hypermethylation. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 3004. doi:10.1007/978-3-642-16483-5_4769Google Scholar
  9. (2012) Radiotherapy. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 3158. doi:10.1007/978-3-642-16483-5_4926Google Scholar
  10. (2012) Resistance. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 3263. doi:10.1007/978-3-642-16483-5_5052Google Scholar
  11. (2012) Rho. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 3302. doi:10.1007/978-3-642-16483-5_5099Google Scholar
  12. (2012) Sarcoma. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 3335. doi:10.1007/978-3-642-16483-5_5161Google Scholar
  13. (2012) Simian virus 40. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 3411. doi:10.1007/978-3-642-16483-5_5307Google Scholar
  14. (2012) Targeted therapy. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 3610. doi:10.1007/978-3-642-16483-5_5677Google Scholar
  15. (2012) TNF-?. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 3713. doi:10.1007/978-3-642-16483-5_5841Google Scholar
  16. (2012) Transcription factor. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 3752. doi:10.1007/978-3-642-16483-5_5901Google Scholar
  17. (2012) Tremolite. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 3782. doi:10.1007/978-3-642-16483-5_5968Google Scholar
  18. (2012) Tumor suppressor. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 3803. doi:10.1007/978-3-642-16483-5_6056Google Scholar
  19. (2012) Two-hit model. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 3821. doi:10.1007/978-3-642-16483-5_6070Google Scholar
  20. (2012) Zeolite. In: Schwab M (ed) Encyclopedia of cancer, 3rd edn. Springer, Berlin/Heidelberg, p 3975. doi:10.1007/978-3-642-16483-5_6297Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Fox Chase Cancer CenterPhiladelphiaUSA
  2. 2.University of Hawaii Cancer CenterHonoluluUSA